Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect

Yang Du, Yinhua Jin, Wei Sun, Junjie Fang, Jianjun Zheng, Jie Tian

Abstract

Objectives This review describes the current status and progress of immune checkpoint targets for imaging of malignancies. Immune checkpoint blockade holds great potential for cancer treatment, and clinical implementation into routine is very rapidly progressing. Therefore, it is an urgent need to become familiar with the vocabulary of immunotherapy and with the evaluation of immune checkpoint and related treatments through noninvasive molecular imaging. Currently, immune target-associated imaging mainly includes PET, SPECT, optical imaging, and MRI. Each imaging method has its own inherent strengths and weaknesses in reflecting tumor morphology and physiology. PD-1, PD-L1, CTLA-4, and LAG-3 are the most commonly considered targets. In this review, the current status and progress of molecular imaging of immune checkpoint targets are discussed.

Conclusion Molecular imaging is likely to become a major tool for monitoring immunotherapy. It can help in selecting patients who are suitable for immunotherapy, and also monitor the tumor response.

Key Points

- Immune checkpoint blockade holds great promise for the treatment of different malignant tumors.
- Molecular imaging can identify the expression of immune checkpoint targets in the tumor microenvironment at the molecular and cellular levels, and therefore helps selecting potential responders, suitable for specific immunotherapy.
- Molecular imaging can also monitor immunotherapeutic effects, and therefore participates in the evaluation of tumor response to treatment.

Keywords Cancer · Immunotherapy · Molecular imaging · Immune checkpoint target

Abbreviations

CTLA-4 Cytotoxic T lymphocyte-associated protein 4
IC Immune checkpoint
LAG-3 Lymphocyte activation gene 3
mAbs Monoclonal antibodies
PD-1 Programmed cell death receptor 1
PD-L1 Programmed death ligand 1
TIL Tumor-infiltrating lymphocytes
TREGS Regulatory T cells
TNBC Triple-negative breast cancer

Introduction

Immune checkpoints (IC) refer to inhibitory pathways in immunoreactions that are momentous for self tolerance. These pathways can suppress T cell effector function leading tumors to evade immune surveillance [1, 2]. IC inhibitors targeting programmed cell death receptor 1 (PD-1) and its ligand (PD-L1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3) are over-expressed in several cancers, such as lung cancer [3], melanoma [4], and triple-negative breast cancer.
(TNBC) [5]. As summarized in Table 1, some IC target inhibitors have been tested in clinical trials. It is reported that IC as PD-1/PD-L1 expression is associated with the poor prognosis of tumors and also with the efficacy of immunotherapy [6].

Molecular imaging is a real-time approach of tumor biomarkers that can accurately monitor the dynamic changes of the target expression and differentiate tumor from normal tissue [7]. The specific radionuclides or optical probes have been developed for the visualization of the immunotherapeutic targets at the molecular and cellular levels. Moreover, molecular imaging can be used for repeated assessment of the same individual before and after the treatment. Immune checkpoint target-associated imaging in the current basic research mainly includes MRI, PET, SPECT, and optical imaging [8]. As every modality has its own strengths and limitations, multimodality imaging is considered to be potentially more powerful. In this review, the current status and future directions of molecular imaging of IC targets on malignancies are discussed (Fig. 1).

### PD-1

PD-1 is an immunosuppressive receptor expressed on immune cells, including activated T cells, regulatory T cells, B cells, monocytes, and dendritic cells (DCs), probably due to stimulation by chronic antigens [9]. There are two PD-1 ligands: PD-L1 and PD-L2. PD-L1 is more widely expressed in cancers than PD-L2. The PD-L1/PD-1 interaction results in the inhibition of T cell activation [10]. PD-1/PD-L1 signaling pathway not only inhibits the activation and function of CD8+ T cells but also enhances the tumor immunosuppressive environment by regulatory T cells (TREGS) [11]. Nivolumab and pembrolizumab are anti-PD-1 mAbs that have been approved by the US Food and Drug Administration (FDA) for the clinical treatment of metastatic melanoma and non-small cell lung cancers [12]. It has been elucidated that PD-1+/FOXP3+ TREGS were detected in the tumor microenvironment, and that PD-1/PD-L1 expression was correlated with poor prognosis of tumors [13]. Hence, PD-1 represents a potential immune target for molecular imaging in cancers. Studies have

| Target | Agent             | Immunotherapy | Immunotherapy targets Imaging |
|--------|-------------------|---------------|-------------------------------|
|        |                   | Basic trial   | Approved | PET | SPECT | Optical Imaging | MRI |
| PD-1   | Nivolumab;        |               |          | △   |       |               | △   |
|        | Pembrolizumab     |               |          | △   |       |               | △   |
|        |                   |               |          | △   | 64Cu  |               | △   |
| PD-L1  | Atezolizumab      |               | △        | △   | △     |               | △   |
|        |                   |               |          | △   | 64Cu,  |               | △   |
|        |                   |               |          |     | 18F   |               | △   |
| CTLA-4 | Tremelimumab      |               | △        | △   | △     |               | △   |
|        | ; Ipiilimumab     |               |          | △   |       |               | △   |
|        |                   |               |          | △   | 64Cu  |               | △   |
|        |                   |               |          | △   | 68Ga  |               | △   |

Table 1  The application of immune checkpoints in clinical trials and the imaging of immune checkpoint targets in malignancies
reported that PD-1 expression can be detected with $^{64}$Cu-labeled anti-PD-1 mAb on tumor-infiltrating lymphocytes (TILs) of B16-F10 melanoma tumors using PET scans. PET imaging has been demonstrated to possess a prognostic value for immunotherapy of PD-1 checkpoint blockade [11]. This was the foundation for PD-1-targeted imaging. Moreover, Du et al synthesized a dual PET and optical dual imaging agents labeled anti-PD-1 mAb, anti-PD-1 mAb-labeled liposomes conjugated with IRDye800CW, and $^{64}$Cu-DOTA to image mouse breast 4T1 tumor with near-infrared fluorescence imaging and PET [14]. A relatively higher PET signal was found in the anti-PD-1 mAb-targeted group compared to the IgG control group, which was consistent with the near-infrared fluorescence (NIRF) imaging (Fig. 2a, b). The data suggested that anti-PD-1 mAb-targeted nanoparticle can effectively target the PD-1 expressing TILs in breast tumor [14].

**PD-L1**

PD-L1, also called CD274, is an immunoinhibitory molecule that suppresses the activation of T cells when binding to the PD-1. It is not only expressed on the surface of tumor cells, but also on antigen-presenting cells in various solid malignancies [16, 17]. There is a close correlation...
between PD-L1 expression and poor prognosis of tumors, especially the digestive system malignancy, urogenital neoplasms, and TNBC [18]. PD-L1-targeted imaging is most frequently studied in malignancies to quantify PD-L1 expression.

SPECT/PET-CT imaging of PD-L1 expression

Heskamp S et al investigated the biodistribution of PD-L1.3.1 mAbs through radiolabeling with indium-111 (111In) for SPECT/CT imaging. 111In-PD-L1.3.1 specifically bound to the high PD-L1-expressing TNBCs (MDA-MB-231 cells) with a heterogeneous distribution [19]. The highest accumulation was observed in the periphery of MDA-MB-231 tumors, whereas the lowest accumulation was found in the tumor center with necrosis. Moreover, 111In-PD-L1-mAb was monitored for specificity using five breast cancer cell lines, and different PD-L1 expression levels were observed (Fig. 2c, d). It has been proven that PD-L1-targeted SPECT/CT imaging is a viable option that can predict the anti-PD-L1 IC therapeutic response in TNBC [15].

PET imaging also provides a noninvasive approach to assess the pharmacokinetics of radiolabeled antibody drugs, which exhibit high affinity for specific antigens. PET imaging commonly used radionuclides that include 64Cu (half-life of 12.7 h), 68Ga (half-life of 68.1 min), and 89Zr (half-life of 3.7 days). Atezolizumab is an anti-PD-L1 antibody used for treating several malignant tumors like non-small cell lung cancer [20], melanoma [21], and TNBC [22]. Lesniak WG et al reported the biodistribution and specific expression of PD-L1 in breast cancer cells using 64Cu-labeled atezolizumab with PET/CT imaging [23]. PET imaging also detected a significantly increased uptake of 64Cu-labeled atezolizumab in MDA-MB-231 tumors compared to SUM149 tumors (low PD-L1-expressing TNBC).

A recent study also showed in vivo dynamic PET imaging of 18F-radiolabeled affibody ligands (NOTA-ZPD-L1.1) in PD-L1-expressing melanoma tumors. The results showed a rapid uptake of the tracer in the PD-L1-positive tumors [24]. Donnelly et al showed PET imaging of mice bearing bilateral PD-L1-positive human lung malignant tumor and PD-L1-negative colon malignant tumor with 18F-BMS-986192 (18F-fluorine labeled anti-PD-L1 adnectin). In vivo PET imaging showed a 3.5-fold higher uptake in PD-L1-positive lung tumor than PD-L1-negative tumor 2 h after injection [25]. Maute et al developed high affinity consensus (HAC) PD-1, a 14-kD protein with high affinity to human PD-L1, and radiolabeled with 64Cu as a PET imaging tracer to measure the expression of PD-L1 on CT-26 colorectal tumor-bearing mice [26]. Mayer et al developed six HAC-PD-1 radiotracer variants to detect human PD-L1 expression, and the data showed that 64Cu-NOTA-HACA-PD1 was the best tracer for monitoring the human PD-L1 expression in vivo. The uptake of 64Cu-NOTA-HACA-PD1 was significantly increased in the PD-L1-positive CT26 tumor and decreased in the nonspecific tissues, but it stays in vessels for a longer time. In order to decrease the blood clearance time, they found that the short half-life 68Ga variants can significantly reduce liver signal when compared with 64Cu variants because 68Ga is known to accumulate in the bone. This study may promote translation of IC imaging into clinical routine [27].

Hettich et al also reported noninvasive PET imaging of PD-1 and PD-L1 tracers in melanoma. Evaluation of 64Cu-NOTA-PD-L1 mAb uptake was performed in mice bearing PD-L1-positive B16F10 melanoma cells and PD-L1-deficient B16F10 cells on the opposing flank. Uptake of 64Cu-NOTA-PD-L1 tracer was detected in the region of PD-L1-positive melanoma, as well as the spleen, the lymph nodes, and the brown adipose tissues, but not in the PD-L1-deficient melanoma [28].

Optical imaging of PD-L1 expression

Optical imaging is widely used to image the abnormalities at the molecular, cellular, and tissue levels in both preclinical and clinical settings. Fluorescent proteins and dyes play important roles in fluorescent molecular imaging studies. The Licor800 dye-conjugated PD-L1-mAb (NIR-PD-L1-mAb)-based imaging probes were utilized to monitor PD-L1 expression in different breast cancer cells. Samit et al found higher fluorescence signal intensities with NIR-PD-L1-mAb in MDA-MB-231 tumors (27% PD-L1-positive tumor cells) compared to SUM149 tumors (0.1% PD-L1-positive cells) (Fig. 2e, f). It demonstrated that the PD-L1-positive expression in TNBC can be specifically detected using a NIR-PD-L1 mAb probe [15].

Optical and MRI dual-modality imaging of PD-L1 expression in tumor

Fluorescence and MRI imaging have the capacity to complement each other. To compensate the insufficiency of each imaging modality, Du et al performed dual-modality MRI and optical fluorescence imaging of PD-L1 expression in breast tumors. Du et al developed a novel theranostic nanoprobe, a PD-L1 mAb-targeted nanoparticle labeled with MRI contrast agent of Gd-DOTA and NIRF fluorescence dye (PD-L1-PCI-Gd). The fluorescence imaging revealed constantly higher fluorescence intensity in PD-L1-targeted nanoparticles in 4T1 tumors compared to the non-targeted control group. The tumor also showed approximately 2-fold higher PD-L1-targeted fluorescence intensity than the background. Similarly, MRI imaging revealed significantly higher signal intensity clearly and persistently in the 4T1 tumors compared to the control group [29].
CTLA-4

CTLA-4 has been identified as the first IC receptor, also called cluster of differentiation 152 (CD152). CTLA-4 is an immune-inhibitory checkpoint that suppresses T cell-mediated immune responses, leading to the development of tumors. CTLA-4 has naturally become a clinically relevant target for imaging that relies on the activation and biodistribution of T cells in vivo. CD28 (cluster of differentiation 28) is one of the proteins expressed on the surface of T cell that promote T cell activation; CTLA-4 and CD28 possess identical ligands: CD80 and CD86 (B7.1 and B7.2). CTLA-4
has a higher affinity for CD80 and CD86 than CD28 that prevents and inhibits the interactions between B7 molecules and CD28, and dampens T cell activation, leading to the inhibition of intracellular signaling [30]. Ipilimumab, an anti-CTLA-4, was approved by the FDA for the treatment of metastatic and high-risk resected melanoma in 2011, and tremelimumab is currently under investigation as another potential anti-CTLA-4.

Initially, Higashikawa et al developed a radionuclide-labeled murine CTLA-4 antibody for imaging CTLA-4-expressing TILs in CT26 tumors. PET imaging was performed to examine the biodistribution and pharmacokinetic properties of $^{64}$Cu-DOTA-anti-CTLA-4 mAb, and the data showed a significantly higher accumulation in the tumor [31]. Recent studies evaluated the biodistribution of $^{64}$Cu-labeled ipilimumab using PET imaging (Fig. 3), with a persistent high accumulation in CTLA-4-expressing lung cancer xenografts. Ipilimumab was found to bind to the CTLA-4-expressing tumor cells [32].

Other immune checkpoints

LAG-3

LAG-3 is a newly discovered immune checkpoint target expressed by activated T lymphocytes, which reduced T cell function [33]. LAG-3-positive TILs were significantly correlated with large mass volume of malignancies, high proliferation, and poor prognosis. The majority of PD-1/PD-L1-positive tumors concurrently show positive LAG-3 expression [34]. The application of multi-target IC blockade is a prospective treatment strategy for malignancies, and imaging of LAG-3 expression may provide evidence for the guidance of immunotherapy.
**Granzyme B**

Checkpoint blocking treatment causes a higher expression of granzyme B, a reliable early-response biomarker for immunotherapy. The study utilized a novel probe $^{68}$Ga-NOTA-GZP to detect granzyme B using PET imaging [35]. Granzyme B is a serine protease released by active tumoral cytotoxic T cells. The immune synapses release granzymes, perforins, and granulysins to the synaptic cleft while binding to the tumor cells. Granzymes and perforins are death-inducing proteins causing the apoptosis of tumor cells [36]. Granzyme B-specific PET imaging was closely associated with granzyme B expression in CT26 colon tumors. The study reported higher radionuclide signal intensity with $^{68}$Ga-NOTA-GZP in tumor with combination treatment of anti-CTLA-4 and anti-PD-1 antibodies, compared to mono immune checkpoint therapy and untreated mice. It was proved that the probe can be utilized to differentiate nonresponders from responders who are suitable for immune checkpoint therapy in a sensitive manner [35] (Fig. 4). Moreover, the study also used an anti-human granzyme B antibody to analyze the human melanoma tumor of patients treated with anti-PD-1 immune checkpoint therapy by immunohistochemistry (IHC). It provides a promising clinical translation for targeted immune checkpoint imaging.

**Conclusion and future perspectives**

Until now, only a fraction of receptors and ligands inhibiting immune responses have been identified and imaged. New generation of IC targets are potentially functional for malignant tumor therapy, such as OX40 (tumor necrosis factor receptor superfamily, also known as CD134), IDO, and TIM3 (T cell immunoglobulin and mucin domain-containing-3). Further imaging studies are needed to explore and monitor their dynamic expression in vivo and also immunotherapeutic effects more accurately. Imaging of immune checkpoint targets may provide further insight into immune therapeutic mechanisms, and is needed for the clinical translation. Moreover, the development of new and more functional imaging techniques is urgently needed to more precisely identify the expression of IC at the molecular and cellular levels. Imaging is helpful for the early diagnosis, cancer staging, and therapeutic effect evaluation. The advent of the new imaging modalities such as magnetic particle imaging (MPI), photoacoustic imaging (PAI), and the combination of several imaging methods is promising for immune-targeted imaging in patients with cancer. Last but not the least, most current studies of molecular imaging of IC targets are still at preclinical stage, and we can expect that clinical trials will develop and multiply in the near future. For this reason, and because we can anticipate that imaging will be a major tool for the evaluation of immunotherapy, imaging

---

**Fig. 4** PET imaging of granzyme B following immune checkpoint blocking. The coronal and axial maximal intensity projection imaging of PET images of anti-PD-1 and anti-CTLA-4 combination-treated (a), anti-PD-1-treated (b), and vehicle-treated (c) colon tumor-bearing mice acquired 1 h postinjection of $^{68}$Ga-NOTA-GZP. The PET imaging showed high radionuclide signal intensity with $^{68}$Ga-NOTA-GZP in tumor with combination treatment of anti-CTLA-4 and anti-PD-1 antibodies. T tumors, K kidneys. (From Larimer BM, with permission of [35]).
specialists need to become familiar with the mechanism of IC and the development of specific drugs, as well as with the technical implementation that will help them to play an important role in this rapidly evolving field.

**Funding** This study has received funding by the Ministry of Science and Technology of China (2017YFA0205200, 2106YFC0103702, 2016YFA0201401, 2015CB755500, and 2014CB748600), National Natural Science Foundation of China (81527805 and 81470083), Beijing Municipal Science and Technology Commission (Z161100002616022), Science Research Fund of National Health and Family Planning Commission-Major Project of Medical and Health Science and Technology in Zhejiang Province (WKJ-ZJ-1807), the Key R&D project of Zhejiang Province (2017C03042), Public Welfare Technology Application Research Project of Zhejiang Province (2017C35003), and the Key Scientific and Technological Special Project of Ningbo City (2015C50004).

**Compliance with ethical standards**

**Guarantor** The scientific guarantor of this publication is Jie Tian.

**Conflict of interest** The authors declare that they have no conflict of interest.

**Statistics and biometry** No complex statistical methods were necessary for this paper.

**Informed consent** Approval from the institutional animal care committee was not required because there is no animal trial in our review.

**Ethical approval** Institutional Review Board approval was not required because there are no human trials in our review.

**Methodology**

- **Prospective**
- **Diagnostic or prognostic study**
- **Multicenter study**

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Ehlerding EB, England CG, McNeel DG, Cai W (2016) Molecular imaging of immunotherapy targets in cancer. J Nucl Med 57:1487–1492
2. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24–33
3. Rzvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128
4. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
5. Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B (2016) Checkpoint inhibitors and their application in breast cancer. Breast Care (Basel) 11:108–1105
6. Taube JM, Klein A, Brahmer JR et al (2014) Association of PD-1, PD-L1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074
7. James ML, Gambhir SS (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92:897–965
8. van de Watering FC, Rijpkema M, Perk L, Brinkmann U, Oyen WJ, Boerma OC (2014) Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int 2014: 203601
9. Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations. Sci Transl Med 8:328rv4
10. Mullard A (2013) New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12:489–492
11. Natarajan A, Mayer AT, Xu L, Reeves RE, Gano J, Gambhir SS (2015) Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug Chem 26:2062–2069
12. Anagnostou VK, Brahmer JR (2015) Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 21:976
13. Muenst S, Soysal SD, Gao F, Obermann EC, Oerlti D, Gillanders WE (2013) The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139:667–676
14. Du Y, Liang X, Li Y et al (2017) Nuclear and fluorescent labeled PD-1-liposome-DOX-64Cu IRDye800CW allows improved breast tumor targeted imaging and therapy. Mol Pharm 14:3978–3986
15. Chatterjee S, Lesniak WG, Gabrielson M et al (2016) A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7:10215–10227
16. Fay AP, Signoretti S, Calla M et al (2015) Programmed death ligand-1 expression in adenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer 3:1–8
17. Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K (2015) Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 88:154–159
18. Mittendorf EA, Philips AV, Meric-Bernstam F et al (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2:361–370
19. Heskamp S, Hobo W, Molenkøber-Kuenen JD et al (2015) Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res 75:2928–2936
20. Spigel DR, Gettinger SN, Horn L et al (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 31:8008
21. Hamid O, Sosman JA, Lawrence DP et al (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 31:9010
22. Schmid P, Cruz C, Brehneth FS et al (2017) Atezolizumab in metastatic TNBC: long-term clinical outcomes and biomarker analyses. Cancer Res 77:2986–2986
23. Lesniak WG, Chatterjee S, Gabrielson M et al (2016) PD-L1 detection in tumors using [(64)Cu]atezolizumab with PET. Bioconjug Chem 27:2103–2110
24. González Trotter DE, Meng X, McQuade P et al (2017) In vivo imaging of the programmed death ligand 1 by 18F positron emission tomography. J Nucl Med 58:1852–1857
25. Donnelly DJ, Smith RA, Morin P et al (2018) Synthesis and biological evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression. J Nucl Med 59:529–535

26. Maute RL, Gordon SR, Mayer AT et al (2015) Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A 112:E6506–E6514

27. Mayer AT, Natarajan A, Gordon SR et al (2017) Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med 58:538–546

28. Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G (2016) High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 6:1629–1640

29. Du Y, Liang X, Li Y et al (2017) Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. Cancer Lett 414:230–238

30. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

31. Higashikawa K, Yagi K, Watanabe K et al (2014) 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One 9:e109866

32. Ehlerding EB, England CG, Majewski RL et al (2017) ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer. Mol Pharm 14:1782–1789

33. Burugu S, Gao D, Leung S, Chia SK, Nielsen TO (2017) LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol 28:2977–2984

34. Bottai G, Raschioni C, Losurdo A et al (2016) An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res 18:121

35. Larimer BM, Wehrenberg-Klee E, Dubois F et al (2017) Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res 77:2318–2327

36. Voskoboinik I, Whisstock JC, Trapani JA (2015) Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol 15:388–400